Switching to B/F/TAF in a Real-World Cohort of Older People With HIV and a High Burden of Non–AIDS-Related Comorbidities

Celia Miralles¹, Berend van Welzen², Sam McConkey³, Benoit Trottier⁴, Daniel Elbirt⁵, Stefan Scholten⁶,

Fabrice Bonnet⁷, Alison Uriel⁸, Rebecca Harrison⁹, Andrea Marongiu⁹, Bhumi Gandhi-Patel¹⁰, Loredana Sarmati¹¹

¹Ålvaro Cunqueiro Hospital, Vigo, Spain; ²University Medical Centre Utrecht, Utrecht, the Netherlands; ³RCSI University of Medicine and Health Sciences, Dublin, Ireland; ⁴Clinique de Médecine Urbaine du Quartier Latin, Montreal, OC, Canada; ³Kaplan Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; ⁶Praxis Hohenstaufenring, Cologne, Germany; ⁷CHU de Bordeaux and University of Bordeaux, INSERM U1219, Bordeaux, France; ⁸North Manchester General Hospital, Manchester, UK; ⁸Gilead Sciences, Stockley Park, Uxbridge, UK; ¹⁹Gilead Sciences, Inc., Foster City, CA, USA;

¹Tor Vergata University, Rome, Italy

Conclusions

- In this large, real-world cohort of people with HIV aged ≥ 50 years who had a high prevalence of comorbidities at baseline, switching to B/F/TAF maintained high levels of effectiveness and was generally well tolerated through 24 months
 - High rates of treatment persistence were maintained at 24 months Treatment satisfaction at 12 months improved after switching to B/F/TAF
 - Lipid, weight, liver, and renal parameters remained stable
- Collectively, these data support the safety of B/F/TAF in older people with HIV and a high prevalence of age-related comorbidities

Plain Language Summary

- People aged 50 years or older who have human immunodeficiency virus (HIV) are more likely to have other medical conditions and often must take lots of different medicines
- The BICSTaR study provides data about an HIV treatment called B/F/TAF when it is used
- In a biochard subject of the analysis of the a
- This summary looks at how B//TAF works in people aged 50 years or older and who have one or more other medical conditions After 2 years of the study, most people:
- - Were still taking B/F/TAF Had amounts of virus in their blood at levels that are too low to be seen on tests
- ('undetectable')
- Were satisfied with their HIV treatment
- Did not have side effects that led to them stopping B/F/TAF

Introduction

- Older people with HIV have an increased prevalence of age-related comorbidities and polypharmacy
- Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single tablet regimen for the treatment of HIV-1 that is widely used in clinical practice and has been shown to be effective in a broad range of people with HIV1
- BICSTaR (BICtegravir Single Tablet Regimen) is a large, multinational, prospective, observational cohort evaluating real-world effectiveness and safety of B/F/TAF in people with HIV^{4,5}
- This pooled analysis of the BICSTaR study included treatment-experienced (TE) people aged \ge 50 years with a high burden of comorbidities and polypharmacy at baseline who switched to B/F/TAF

Objective

To evaluate the 24-month effectiveness and tolerability of switching to B/F/TAF in people aged ≥ 50 years with (or history of) ≥ 1 comorbidity at baseline

Methods



F and occurring within 24 month enamide; BICSTaR, BICtegravir n; PRO, patient-reported outcon *Any HIV AE considered by the investigator AE, adverse event; B/F/TAF, bictegravir/em HIVTSQc, HIV Treatment Satisfaction Ques copies; DRAE, drug-related adverse event Single Tal

Comorbidities at Baseline

- Information on comorbidities was collected using predefined categories (see Table below) and "Other" as free text
- The "Other" category as used to report comorbidities as free text using the Medical Dictionary for Regulatory Activities (MedDRA), Version 24.1, coding system"
 The information collected by the predefined comorbidity categories had varying degrees of granularity eg, for neuropsychiatric, cardiovascular, and categories licorders, no detail was collected on specific disorders
 All predefined comorbidity categories were mapped to MedDRA's Highest Level Term 1, System Organ Class (SOC), to harmonise the information collected at MedDRA Lovest Level Term (LLT) with those collected at SOC level as well as the information in the "Other" category

eCRF	MedDRA Level of eCRF Comorbidity	Mapping	
Comorbidity Categories	Categories ⁷		MedDRA SOC Term 1
Asthma	Lowest Level Term	l→	Respiratory, thoracic, and mediastinal disorders
Chronic hepatitis B	Lowest Level Term	l→	Infections and infestations
Chronic hepatitis C	Lowest Level Term	l→	Infections and infestations
COPD	Lowest Level Term	l→	Respiratory, thoracic, and mediastinal disorders
Diabetes mellitus	Lowest Level Term		Metabolism and nutrition disorders
Hyperlipidemia	Lowest Level Term		Metabolism and nutrition disorders
Hypertension	Lowest Level Term		Vascular disorders ^b
Renal insufficiency	Lowest Level Term		Renal and urinary disorders
Cardiovascular	System Organ Class		Cardiac disorders ^b
Neuropsychiatric disorder	System Organ Class] ───→	Psychiatric disorders
Osteopathic disorder ^a	System Organ Class] ───→	Musculoskeletal and connective tissue disorders

*Not available on Med/RA classification system, so mapping term has been inferred.
*Cardiac and vascular disorders were combined into "Cardiovascular disorder" since these are not distinguished in the baseline comobidity existing categories eGRF, electroinc case report form; Med/RA, Medical Dictionary for Regulatory Activities; SOC, System Organ Class.

Results


	N = 401
Sex at birth, n (%)	
Male / Female	344 (86) / 57 (14)
Race, n (%)	
White / Black / Other ^a	326 (81) / 49 (12) / 26 (6)
Age at B/F/TAF initiation, years, median (Q1, Q3)	56 (53, 62)
Age ≥ 65 years, n (%)	74 (18)
HIV-1 RNA < 50 c/mL, n/N (%)	335/356 (94)
CD4 count, cells/µL, n (%)	
< 350 / < 200	53 (16) / 11 (3)
Prior ART, n (%)	
INSTI / PI / NNRTI / TDF	261 (65) / 65 (16) / 84 (21) / 140 (35)
HIVTSQs score. ^b median (range)	57 (17-60) [n = 129]

References: 1. Kasale P, et al. Oral 102 presented al: CROI: March 6-10, 2021; Venual 2. McNichal IR, et al. Pharmacotherapy. 2017;37 3. PektorhaMathews A, et al. AUGS. 2018;32:2045;16. 4. Esser S, et al. HV/Med: 2024;25:4045;3. 6. Caucia-Debtor M, et al. Poter 160 27:30, 2022; Signs: Son B. Heaht Poycholy Research LIR. Royal Veldoway, University of Lordon, https://www.medsta.org 10:4004/Heaht Organization. https://www.medsta.org 10:4004/Heaht Organization.https://www.medsta.org 10:400 d Sciences, Inc. (GS-EU-380-4472/GS-CA-380-4 ted by Gilead Sciences, Inc. Crivin-10

	TE (N = 401)
Complex medical history, ^a n (%)	335 (84)
Comorbidities, n (%) ≤ 2 / > 2 / > 3 / > 4	142 (35) / 259 (65) / 186 (46) / 131 (33)
Comorbidities across multiple SOCs, n (%) $\leq 2 / > 2 / > 3 / > 4$	173 (43) / 228 (57) / 136 (40) / 86 (17)
Most frequent comorbidities by SOC (2 30%), n (%) Cardiovascular disorders Metabolism and nutrition disorders Infections and infestations Psychiatric disorders	193 (48) 191 (48) 138 (34) 136 (34)
Polypharmacy (≥ 5 comedications), n (%)	87 (22)
Number of comedications per person, median (Q1, Q3)	2 (1, 4)
Most frequent comedications by pharmacological or therapeutic subgroup (2 eVs), n (%) Analgesics Lipid-modifying agents Agents acting on the renin-anglotensin system Vitamins	141 (8) 126 (7) 114 (6) 110 (6)
Psycholeptics	98 (5)

⁴CD4 count < 200 cells/µL or ≥ 2 comorbidities or ≥ 5 concomitant medications at switch to B/F/TAF. ^bAnatomical Therapeutic Council 2nd-level cla B/F/TAF. bictegravir/remtricitable/tendrovir alafenamide: Q. guartile: SQC. System Organ Class: TE, treatment-experienced.

Virologic Effectiveness Through 24 Months



Of participants who were not virologically suppressed at baseline (n = 16),^c 81% (n = 13) achieved HIV-1 RNA < 50 c/mL at 24 months after switching to B/F/TAF

Denominator = number of participants in each subgroup with data as $^{12}CD4$ count < 200 cells/µL or \geq 2 comorbidities or \geq 5 concomitant m can Indian or Alaska Native, Asian, Not Permitted, and Other "Includes Amer



Immunologic Outcomes at 24 Months

Median (Q1, Q3)		Baseline		Median (Q1, Q3) change at 24 months	
CD4 count, cells/µL	n = 252	622 (449, 864)	\rightarrow	+40 (-66, 150)	\supset
					5
		CD4 count, cells/µL n = 252	CD4 count, cells/µL n = 252 622 (449, 864)	CD4 count , cells/ μ L n = 252 622 (449, 864) \rightarrow	Median (Q1, Q3) Baseline change at 24 months CD4 count, cells/µL n = 252 622 (449, 864) → +40 (-66, 150)

×Q*

Treatment Persistence and Satisfaction Outcomes

90%

f people were still taking B/F/TAF at 24 months (359/401)^a

"Reasons for discontinuation, n (%): adverse event, 28 (7); death, 8 (2); investigator's discretion, 4 (1); lack of efficacy, 2 (1); new tre participant's decision, 3 (1). B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide. ole, 1 (< 1);



HIVTSQc score ranges from -30 to 30, the higher the score, the greater the improvement in satisfaction with treatment; *12 months is r the assessment of change, as later assessments may be subject to participant recall bias⁶; *Median (Q1, Q3). HIVTSQc. HIV Traintents Satisfaction Questionate reviews waterior. Or usual -

Adverse Events at 24 Months



Total number of DRAE reports: n = 76, ¹206 in single participant; ¹Total number of DRAEs leading to discontinuation: n = 37. AE, adverse event; B/FT/AF, bickgrav/ir/emticitabine/ temo/ovir addenamide; DRAE, drug-related adverse event; DRSAE, drug-related serious adverse event M/DRSDe INI: Charamed Selection: Doublecomics of home: number of number of

Clinical Changes at 24 Months

	Median (Q1, Q3)		Baseline		Median (Q1, Q3) change at 24 months
۲	eGFR, mL/min	n = 204	85 (74, 102)	\rightarrow	-5.0 (-13.7, 1.8)
١	ALT, U/L	n = 263	24 (19, 32)	\rightarrow	+1.0 (-4.0, 7.4)
١	AST, U/L	n = 220	25 (21, 31)	\rightarrow	+1.0 (-4.0, 5.0)
١	TC, mmol/L	n = 197	5 (4, 6)	\rightarrow	-0.0 (-0.7, 0.5)
١	TC:HDL ratio	n = 173	4 (3, 5)	\rightarrow	-0.1 (-0.6, 0.5)
١	LDL, mmol/L	n = 167	3 (2, 3)	\rightarrow	0.0 (-0.5, 0.5)
ā	Weight, kg	n = 229	76 (66, 86)	\rightarrow	+1.0 (-1.3, 3.2)
tt	BMI, kg/m ²	n = 229	25 (23, 28)	\rightarrow	+0.3 (-0.5, 1.2)

n = number of participants with data available at both baseline and 24 months. eGFR, estimated glomerular filtration rate: HDL, high-density ipoprotein cholesteroi: Q, guartile: TC, total ch

Limitations

on comorbidities at baseline was collected using predefined categories with varying degrees of granularity to a mixture of MedDRA LLTs and SOCs The information that correspond

Sciences, inc. and consulting loses and research support from Galeed Sciences, inc. and VVI Healthcare. BWV reports research based Sciences, inc. and VVI Healthcare. Ski Proports on disclosers of Internet. BT project consultant for twords grants based Sciences, inc. and VVI Healthcare. Ski Proports and sciences in the science of the science of the science is in a more science of the science of thcare; and consultant es from C e. DE rep and ViV Healthcare; and congress supp , and ViV Healthcare. AU has no conflict iences, Inc. LS reports consultant and sp Glead Sciences, Inc., GSK, a Glead Sciences, Inc., MSD, a and hold stock in Glead Scien I reports travel grants, speaker fees, and congress support fin ences, Inc. at the time of the study. AM and BG-P are employ a, Gilead Sciences, Inc., GSK, and Merck. It from Glead Sciences, Inc. and VIV Healthcare f interest to report. RH was a contractor at Glead